0.993
price down icon1.68%   -0.017
after-market Handel nachbörslich: 1.01 0.017 +1.71%
loading
Schlusskurs vom Vortag:
$1.01
Offen:
$0.99
24-Stunden-Volumen:
698.39K
Relative Volume:
1.00
Marktkapitalisierung:
$78.11M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-1.1821
EPS:
-0.84
Netto-Cashflow:
$-56.88M
1W Leistung:
-0.60%
1M Leistung:
-13.65%
6M Leistung:
-77.58%
1J Leistung:
-21.19%
1-Tages-Spanne:
Value
$0.99
$1.01
1-Wochen-Bereich:
Value
$0.9886
$1.07
52-Wochen-Spanne:
Value
$0.9882
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Firmenname
Cytomx Therapeutics Inc
Name
Telefon
650.515.3185
Name
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
122
Name
Twitter
@cytomxinc
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
CTMX's Discussions on Twitter

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-05-28 Hochstufung Piper Sandler Neutral → Overweight
2024-05-09 Hochstufung Wedbush Neutral → Outperform
2024-05-06 Hochstufung Jefferies Hold → Buy
2024-04-22 Hochstufung JP Morgan Underweight → Neutral
2022-11-14 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-07-07 Herabstufung Jefferies Buy → Hold
2022-07-07 Herabstufung Mizuho Buy → Neutral
2022-07-07 Herabstufung Piper Sandler Overweight → Neutral
2022-07-07 Herabstufung Wedbush Outperform → Neutral
2022-06-24 Eingeleitet BMO Capital Markets Outperform
2022-01-18 Hochstufung Barclays Underweight → Overweight
2021-11-15 Eingeleitet BTIG Research Buy
2021-05-28 Herabstufung Barclays Equal Weight → Underweight
2021-03-29 Eingeleitet JP Morgan Overweight
2021-03-23 Hochstufung Jefferies Hold → Buy
2020-09-22 Herabstufung Guggenheim Buy → Neutral
2020-06-01 Herabstufung Jefferies Buy → Hold
2020-05-14 Bestätigt H.C. Wainwright Buy
2020-03-24 Hochstufung Wedbush Neutral → Outperform
2020-03-04 Eingeleitet Barclays Equal Weight
2019-11-20 Eingeleitet Guggenheim Buy
2019-11-11 Herabstufung Wedbush Outperform → Neutral
2019-06-13 Eingeleitet Mizuho Buy
2019-05-14 Eingeleitet Cantor Fitzgerald Overweight
2019-03-11 Eingeleitet Barclays Overweight
2018-11-26 Eingeleitet Piper Jaffray Overweight
2018-10-15 Eingeleitet Goldman Neutral
2018-09-13 Eingeleitet H.C. Wainwright Buy
2018-06-01 Eingeleitet SunTrust Buy
2018-01-05 Eingeleitet Citigroup Buy
2017-09-08 Eingeleitet Wedbush Outperform
2017-03-27 Eingeleitet H.C. Wainwright Buy
2017-03-02 Eingeleitet Instinet Buy
2017-01-03 Herabstufung Oppenheimer Outperform → Perform
2015-11-02 Eingeleitet Oppenheimer Outperform
Alle ansehen

Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten

pulisher
Nov 03, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 17, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle

Oct 15, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily

Oct 11, 2024
pulisher
Oct 06, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 06, 2024
pulisher
Sep 30, 2024

There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News

Sep 30, 2024
pulisher
Sep 29, 2024

Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News

Sep 26, 2024
pulisher
Sep 25, 2024

Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech

Sep 25, 2024
pulisher
Sep 24, 2024

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Reports Narrowed Losses - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN

Sep 23, 2024
pulisher
Sep 22, 2024

XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat

Sep 21, 2024
pulisher
Sep 21, 2024

Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

622,616 Shares in ChampionX Co. (NASDAQ:CHX) Bought by Renaissance Technologies LLC - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Coherent (COHR) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

CTMX: A Tale of Ups & Downs – -48.46% loss in 6 Months, -5.65% in 30 Days - The InvestChronicle

Sep 20, 2024
pulisher
Sep 20, 2024

Insider Selling: Landau Jeffrey B, CytomX Therapeutics Inc [CTMX] Chief Business Officer divested 4,181 shares - Knox Daily

Sep 20, 2024
pulisher
Sep 20, 2024

Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Top 2% Biotech Hits Slam Dunk On Bid To Edge Out Bristol, Cytokinetics - Investor's Business Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex

Sep 19, 2024
pulisher
Sep 19, 2024

Autolus Therapeutics (AUTL) Appoints Matthias Will as Chief Development Officer - StreetInsider.com

Sep 19, 2024
pulisher
Sep 18, 2024

Analyzing CTMX’s price-to-book ratio for the last quarter - US Post News

Sep 18, 2024
pulisher
Sep 17, 2024

Altamira Therapeutics prices up to $12M public offering - MSN

Sep 17, 2024
pulisher
Sep 16, 2024

Keeping an Eye on CytomX Therapeutics Inc (CTMX) After Insider Trading Activity - Knox Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Check Out CytomX Therapeutics Inc (CTMX)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex

Sep 16, 2024
pulisher
Sep 16, 2024

HC Wainwright Reaffirms Neutral Rating for CytomX Therapeutics (NASDAQ:CTMX) - Defense World

Sep 16, 2024
pulisher
Sep 13, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns Neutral Rating from HC Wainwright - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

Acadian Asset Management LLC Acquires 37,739 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 13, 2024
pulisher
Sep 12, 2024

Candriam S.C.A. Invests $256,000 in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 12, 2024
pulisher
Sep 11, 2024

Market Watch Highlights: CytomX Therapeutics Inc (CTMX) Ends on an Upturn Note at 1.31 - The Dwinnex

Sep 11, 2024
pulisher
Sep 11, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sep 11, 2024

Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Sale
1.23
4,181
5,139
119,056
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
179,829
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Sale
1.23
4,181
5,139
175,648
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Option Exercise
0.00
11,250
0
134,978
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Sale
1.23
4,181
5,139
130,797
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Option Exercise
0.00
6,875
0
110,061
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Sale
1.23
1,984
2,439
108,077
McCarthy Sean A.
CEO
Aug 20 '24
Option Exercise
0.00
37,500
0
671,749
McCarthy Sean A.
CEO
Aug 20 '24
Sale
1.23
13,898
17,082
657,851
McCarthy Sean A.
CEO
Mar 26 '24
Option Exercise
1.57
109,768
172,874
634,249
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):